Pramipexole as adjunct to haloperidol in schizophrenia Safety and efficacy

Pramipexole, a presynaptic dopamine D2/D3 autoreceptor agonist, has been given to haloperidol-treated patients with schizophrenia (n = 15) in an effort to ameliorate residual positive and negative symptoms that have not been satisfactorily influenced by haloperidol alone. Total scores of the positive and negative symptom scale (PANSS) decreased by more than 20% in 9 of 15 patients (reduction of total score: 22-62%). Serious adverse events did not occur. Three of the 15 patients dropped out due to worsening of schizophrenia. Insomnia, as the most frequent side effect, occurred in 4 patients. No clinically relevant electrocardiographic and laboratory changes were reported. This study supports the safety of the treatment of schizophrenia with pramipexole and haloperidol as a combination therapy. However, further clinical studies are required to support these preliminary findings.

[1]  M S Buchsbaum,et al.  Glucose Metabolic Rate in Normals and Schizophrenics During the Continuous Performance Test Assessed by Positron Emission Tomography , 1990, British Journal of Psychiatry.

[2]  Takeshi Inoue,et al.  B-HT 920, a dopamine D2 agonist, in the treatment of negative symptoms of chronic schizophrenia , 1993, Biological Psychiatry.

[3]  R. Olbrich,et al.  The effect of the partial dopamine agonist terguride on negative symptoms in schizophrenics. , 1988, Pharmacopsychiatry.

[4]  H. J. Cormier,et al.  Qui Sont Les Patients Traités en Clinique Externe Avec des Doses Élevées de Neuroleptiques? * , 1990 .

[5]  A. Mackay,et al.  Positive and Negative Schizophrenic Symptoms and the Role of Dopamine , 1980, British Journal of Psychiatry.

[6]  D. Ingvar,et al.  ABNORMALITIES OF CEREBRAL BLOOD FLOW DISTRIBUTION IN PATIENTS WITH CHRONIC SCHIZOPHRENIA , 1974, Acta psychiatrica Scandinavica.

[7]  H. Möller,et al.  Early clinical results with the neuroleptic roxindole (EMD 49 980) in the treatment of schizophrenia — an open study , 1992, European Neuropsychopharmacology.

[8]  G. Simpson,et al.  A RATING SCALE FOR EXTRAPYRAMIDAL SIDE EFFECTS , 1970, Acta psychiatrica Scandinavica. Supplementum.

[9]  C. Tamminga,et al.  Schizophrenic symptoms improve with apomorphine. , 1978, Science.

[10]  F. J. White,et al.  A10 dopamine neurons: role of autoreceptors in determining firing rate and sensitivity to dopamine agonists. , 1984, Life sciences.

[11]  W. Kissling,et al.  Erste klinische Erfahrungen mit dem neuen Dopamin-Autorezeptoragonisten SND 919 , 1992 .

[12]  Lewis A. Opler,et al.  Reliability and validity of the positive and negative syndrome scale for schizophrenics , 1988, Psychiatry Research.

[13]  B. Jones,et al.  Evidence of Brain Dopamine Deficiency in Schizophrenia , 1979, Canadian journal of psychiatry. Revue canadienne de psychiatrie.

[14]  H. Wetzel,et al.  Dopamine Autoreceptor Agonists in the Treatment of Schizophrenia and Major Depression* , 1992, Pharmacopsychiatry.

[15]  J. Lieberman,et al.  The Hillside Akathisia Scale: a new rating instrument for neuroleptic-induced akathisia. , 1989, Psychopharmacology bulletin.

[16]  D. Weinberger,et al.  Physiologic dysfunction of dorsolateral prefrontal cortex in schizophrenia. I. Regional cerebral blood flow evidence. , 1986, Archives of general psychiatry.

[17]  H. Meltzer.  Relevance of dopamine autoreceptors for psychiatry: preclinical and clinical studies. , 1980, Schizophrenia bulletin.

[18]  S. Steingard,et al.  Optimal dose of neuroleptic in acute schizophrenia. A controlled study of the neuroleptic threshold and higher haloperidol dose. , 1991, Archives of general psychiatry.